Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
biocon biosimilars
November 2022
February 2022
January 2022
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
Biocon developing 20 biosimilar products for global markets
Biocon, which launched the world's first interchangeable insulin Glargine in the US during the third quarter, has eight approved products.
